BCM
RUBY

Bayesian Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Bayesian Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,080
Closed -$12K – 1099
2022
Q2 		$12K Buy
+14,080
New +$23.6K ﹤0.01% 740

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Bayesian Capital Management's RUBY Position: Q3 2022 in Review

Bayesian Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 14,080 shares — an estimated $12K sold.

Bayesian Capital Management first reported a position in RUBY in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Bayesian Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 14,080 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $12K.
  • Bayesian Capital Management first reported a position in Rubius Therapeutics, Inc in Q2 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Rubius Therapeutics, Inc position peaked at $12K in Q2 2022.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.